Celcuity Q1 net loss $21.6M; Phase 3 VIKTORIA-1 on track for H2 2024 data

Celcuity Inc.

2024-Q1 EPS reported -$0.64

Net loss $21.6M ($0.64/sh) vs $11.9M ($0.55/sh) in Q1 2023; cash $177.7M expected runway into H1 2026.
Phase 3 VIKTORIA-1 on track: topline PIK3CA wild-type data H2 2024; mutant sub-group H1 2025.
First patient dosed in Phase 1b/2 trial of gedatolisib + darolutamide for mCRPC; prelim data expected H1 2025.
Appointed Eldon Mayer as CCO in Feb 2024 to prepare for potential gedatolisib launch.
R&D expenses $20.7M (up $9.4M YoY) driven by VIKTORIA-1 and new trial initiation.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Celcuity Inc. reported the first quarter ended March 31, 2024 results: net income Net loss for the first quarter of 2024 was $21.6 million, or $0.64 loss per share, EPS $0.64 loss per share.

Period: the first quarter ended March 31, 2024
Net income: Net loss for the first quarter of 2024 was $21.6 million, or $0.64 loss per share
EPS: $0.64 loss per share
Result: reported results

Exact text from the filing

Celcuity Inc. (the “Company”) issued a press release regarding the Company’s financial results for the first quarter ended March 31, 2024.

View on SEC.gov

Browse all earnings releases →

Celcuity Inc. filing history →

Source: SEC EDGAR

accession 0001493152-24-019852

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.